Deep inside your large intestine, a thin but critical barrier separates trillions of microbes from your bloodstream. That barrier is the mucus layer: a gel-like coating produced continuously by goblet cells lining the intestinal wall. Most gut bacteria keep their distance from this layer, but one species, Akkermansia muciniphila, makes it home.
Research interest in Akkermansia has grown steadily because its unusual niche, living directly within the mucus, appears to be central to how it interacts with host physiology. Understanding why this bacterium chooses the mucus layer, and what it does there, helps explain why scientists are investigating it in the context of metabolic health, intestinal barrier integrity, and GLP-1 signaling.
Key Takeaways
- Akkermansia muciniphila is uniquely adapted to colonize the intestinal mucus layer by encoding enzymes that break down mucin glycans for nutrients.
- Its proximity to the epithelium is central to proposed mechanisms involving tight-junction support, barrier integrity, and GLP-1 stimulation, but most mechanistic data are from animal and cell models.
- The outer-membrane protein Amuc_1100 is a focus of research because of its potential to activate anti-inflammatory TLR2 signaling; pasteurized formulations retain this protein.
- Human trials are few and mixed: a 2019 pilot found improved insulin sensitivity with pasteurized Akkermansia, while a larger 142-adult trial missed its primary endpoint [6][7].
- Fiber and polyphenol intake have been linked to higher Akkermansia abundance in some studies, but few diet trials exist and the polyphenol evidence is mostly from mice [8][9][10].
What the Gut Mucus Layer Actually Is
The intestinal mucus layer is not static slime: it is a dynamic, structured hydrogel composed primarily of MUC2 glycoproteins secreted by goblet cells. In the colon, this layer exists in two zones: a dense inner layer that is largely sterile and sits directly on the epithelium, and a looser outer layer where most commensal microbes reside.[1]
The mucus layer serves several simultaneous functions. It acts as a physical barrier preventing luminal bacteria and their products from reaching epithelial cells and triggering inflammation. It also provides lubrication for the passage of intestinal contents, and, critically for Akkermansia, it contains an enormous supply of glycans that can serve as a carbon and nitrogen source for specialized bacteria.[2]
Goblet cells constantly replenish mucin secretions, meaning the mucus layer turns over regularly. Any organism that degrades mucins faster than they are replaced risks compromising barrier function. A key question in Akkermansia research is whether the bacterium’s mucin-degrading activity is ultimately net-positive (stimulating faster renewal and upregulating tight junctions) or whether it can become problematic under certain conditions.
How Akkermansia Establishes Its Niche in Mucus
Akkermansia muciniphila encodes a large repertoire of carbohydrate-active enzymes, glycoside hydrolases and sulfatases, that allow it to break down the O-glycan side chains decorating MUC2 mucins.[3] This capacity for mucin degradation is rare among gut commensals and explains why Akkermansia can thrive in an ecological zone where most organisms cannot compete for nutrients.
Research note: A review cites infant data: A. muciniphila was detectable in 72% of infants at 6 months and 90% at 12 months [29].
Genome sequencing found numerous candidate mucinase-encoding genes but no genes for canonical mucus-binding domains, so how the bacterium stays anchored in the mucus layer is not settled [3]. Among these outer-membrane components, the Amuc_1100 protein has received particular attention from researchers because of its proposed interactions with host immune and metabolic signaling pathways.
Akkermansia was found at more than 1% of faecal cells in one study of human samples, but abundance varies widely, from under 0.01% to nearly 4% of assembled reads in 37 metagenomes. It has been reported to be lower in obesity and type 2 diabetes, while findings on age are mixed. These observations have motivated studies asking whether restoring its abundance might reverse some of those associated health changes [11][3][12][13][14][15].
The Mucus Layer Connection to Intestinal Barrier Integrity
A healthy mucus layer is one of the first lines of defense against what researchers call ‘leaky gut’: increased intestinal permeability that allows bacterial lipopolysaccharides (LPS) and other immune-activating molecules to reach systemic circulation. When the mucus layer thins or becomes disrupted, the underlying epithelium is exposed to luminal contents that would normally never contact it.
Proposed mechanisms by which Akkermansia may support barrier integrity include upregulation of tight-junction proteins such as claudin-3 and occludin, which seal the spaces between adjacent epithelial cells. Some research suggests that Akkermansia-derived metabolites and outer-membrane proteins signal goblet cells to increase mucin production: a potential positive feedback loop where controlled mucin degradation stimulates faster mucin renewal rather than net depletion.[4]
It is important to be precise here: most mechanistic evidence on these pathways comes from mouse models and cell-line studies. Human data on intestinal permeability endpoints are more limited and less consistent, and the field has not yet established clear causality between Akkermansia colonization and improved barrier function in humans.
Amuc_1100: The Outer-Membrane Protein Drawing Attention
Among the structural components of Akkermansia, the outer-membrane protein Amuc_1100 has been studied because it appears to activate Toll-like receptor 2 (TLR2) on intestinal epithelial and immune cells. TLR2 signaling in this context is associated with anti-inflammatory responses and reinforcement of tight-junction complexes: a different outcome from the inflammatory TLR4 signaling triggered by gram-negative LPS.[5]
Preclinical work with heat-treated Akkermansia (which retains Amuc_1100 on intact outer-membrane vesicles) has shown effects comparable to or exceeding those seen with live bacteria in some metabolic models.[5] This is one reason some commercially available formulations use pasteurized rather than live Akkermansia: an approach that also addresses safety concerns around live probiotic use in vulnerable populations.
Mouse results on live versus heat-treated cells are not uniform. In one mouse study the metabolic benefits required viable cells, and heat-killed cells did not improve the metabolic profile or mucus layer thickness. In a mouse immunotherapy study, live cells were the most effective form at activating CD8 T cells [4][28].
Human clinical data on Amuc_1100 specifically are early. Researchers are working to determine whether the concentrations of Amuc_1100 that produce effects in cell culture are achievable at the mucosal surface following oral supplementation, and whether individual variation in existing Akkermansia colonization modulates the response.
GLP-1 Secretion and Metabolic Connections
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by enteroendocrine L-cells in the intestinal epithelium. It stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and promotes satiety. Because Akkermansia resides close to the epithelium where L-cells are concentrated, researchers have proposed that its metabolic outputs, including short-chain fatty acids from mucin fermentation, may directly stimulate GLP-1 release.
Human trials of pasteurized Akkermansia are few. A 2019 pilot in overweight or obese insulin-resistant adults reported improved insulin sensitivity versus placebo, while a later placebo-controlled trial of 142 adults with metabolic syndrome, using 30 billion pasteurized cells daily, did not change its primary endpoint of insulin sensitivity [6][7]. However, the trials have been small, short in duration, and conducted in specific populations: findings should not be generalized to all individuals or treated as equivalent to pharmaceutical interventions.
It is also worth noting that the gut microbiome is a complex ecosystem. Changes in Akkermansia abundance do not occur in isolation; shifts in one species typically ripple through community structure in ways that are difficult to attribute to a single organism.
What Influences Akkermansia Abundance Naturally
Diet is the most modifiable driver of Akkermansia colonization. Evidence for fiber is mixed: inulin raised Akkermansia in a 60-person trial in people with overweight or obesity and diabetes (as summarized in a review), but not in a pilot of 49 adults with type 1 diabetes. Cranberry and green tea extracts raised Akkermansia in mice, and a systematic review of dietary trials found only five of 29 trials examined Akkermansia alone [8][16][9][10].
In mice, a high-fat diet thinned the colonic mucus layer and depleted Akkermansia, and chronic restraint stress lowered it. Antibiotic use has been associated with low Akkermansia in cancer patients, but oral vancomycin raised it in a small inpatient study. Findings on age are mixed: young adults had less Akkermansia than elderly people in one study, and Chinese centenarians had less than younger elderly people [17][18][19][20][14][15].
For individuals interested in supporting Akkermansia through diet before considering supplementation, increasing dietary fiber diversity and reducing ultra-processed food intake is a reasonable general approach, although trials have not shown that it raises Akkermansia enough to change health outcomes [8]. Whether direct supplementation adds meaningfully beyond dietary approaches has not yet been established in head-to-head trials.
🛒 Where to Buy Akkermansia muciniphila
- Pendulum Akkermansia
delayed-release capsules, 100M AFU: Live A. muciniphila strain (WB-STR-0001); single-strain with chicory inulin, third-party tested. - Codeage Akkermansia Muciniphila
capsules, 100M AFU, 90 ct: Lower-cost Akkermansia plus chicory inulin synbiotic; 3-month supply, gluten-free. - Double Wood Akkermansia Probiotic + Postbiotic
capsules, per label: Budget Akkermansia option marketed around GLP-1 and postbiotic support.
As an Amazon Associate we earn from qualifying purchases. Akkermansia is a live, oxygen-sensitive strain: choose a delayed-release, third-party-tested product with a stated live AFU count.
A Note on the Evidence
The human evidence base for Akkermansia supplementation remains early: most trials are small, short-term, and conducted in specific populations; findings should not be extrapolated broadly. Individuals who are immunocompromised, taking immunosuppressive medications, pregnant, or managing active inflammatory bowel disease should consult a qualified healthcare provider before using any live or pasteurized probiotic supplement. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Is Akkermansia supposed to be in my gut?
Yes. Akkermansia muciniphila is a natural resident of the human gut, found at more than 1% of faecal cells in one study of human samples, though abundance varies widely and it was undetectable in 45.3% of 786 older Japanese adults [11][21]. Its absence or very low abundance has been associated with metabolic and inflammatory conditions in observational research, though whether low abundance causes those conditions or results from them remains an active area of investigation.
Does Akkermansia actually damage the mucus layer by eating it?
This is a reasonable concern. Akkermansia does degrade mucin glycans, but proposed positive feedback mechanisms suggest that controlled degradation may stimulate goblet cells to increase mucin production, resulting in net renewal rather than depletion. Mouse results are mixed: some studies found Akkermansia helpful where the mucus layer was already thin, while a review warns that in a damaged gut barrier or on a low-fiber diet it can over-proliferate, speed mucus breakdown and worsen inflammation, and in one mouse study a beef-protein diet expanded Akkermansia alongside thinner mucus and the most severe colitis. Human data are too limited for firm conclusions [22][23].
What is Amuc_1100 and why do supplement labels mention it?
Amuc_1100 is an outer-membrane protein of Akkermansia that has been studied for its ability to interact with TLR2 receptors on intestinal and immune cells, potentially supporting anti-inflammatory signaling and tight-junction integrity. It is heat-stable, meaning pasteurized Akkermansia formulations retain it. Some supplement manufacturers highlight Amuc_1100 content as a quality marker, though human clinical data on this specific protein are still early.
Can I raise my Akkermansia levels through diet alone?
Dietary approaches, such as inulin-rich prebiotic fibers (chicory root, garlic, onions, Jerusalem artichoke) and polyphenol-rich foods (pomegranate, cranberry, green tea), have been linked to higher Akkermansia abundance in some studies, but inulin did not raise it in a type 1 diabetes pilot and most polyphenol data are from mice. Few diet trials exist, so diet is a reasonable general first step but not a proven way to raise Akkermansia [8][16][9][10].
Is it safe to take an Akkermansia supplement?
For healthy adults, EFSA found pasteurised Akkermansia safe at 3.4 x 10^10 cells/day, excluding pregnant and lactating women, and adverse events were balanced with placebo in a 142-adult trial, though EFSA judged the 2019 pilot of limited value for safety. Live probiotic formulations carry potential risks for immunocompromised individuals, those on immunosuppressive therapy, or people with active inflammatory bowel disease. Pasteurized formulations may reduce but not eliminate risk, since EFSA could not rule out harm from even very low live-cell exposure in susceptible people. Anyone in these categories should consult a physician before use. Akkermansia supplements are not FDA-approved to treat, cure, or prevent any disease [27][7].
How is Akkermansia related to GLP-1 and blood sugar?
Akkermansia resides near L-cells in the intestinal epithelium that secrete GLP-1, an incretin hormone involved in insulin regulation and satiety. A narrative review calls Akkermansia GLP-1-agonistic but says more human research is needed. In cells and mice, a secreted Akkermansia protein (P9) and a peptide raised GLP-1, but this has not been shown in people. A 2019 pilot reported improved insulin sensitivity with pasteurized Akkermansia, while a later 142-adult trial missed its primary endpoint, so these findings should not be interpreted as a treatment for diabetes or prediabetes [24][25][26][6][7].
References
- Johansson ME et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proceedings of the National Academy of Sciences of the United States of America (2008). PMID 18806221
- Derrien M et al. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. International journal of systematic and evolutionary microbiology (2004). PMID 15388697
- van Passel MW et al. The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PloS one (2011). PMID 21390229
- Everard A et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proceedings of the National Academy of Sciences of the United States of America (2013). PMID 23671105
- Plovier H et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature medicine (2017). PMID 27892954
- Liu Y et al. Pasteurized Akkermansia muciniphila as a candidate multi-effector pharmacological system in the gut-liver axis: evidence, unresolved causality, and translational priorities. Frontiers in pharmacology (2026). PMID 42846334
- Suenaert P et al. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels. Gut microbes (2026). PMID 42343233
- Sanne Verhoog et al. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients (2019). PMID 31336737
- Fernando F. Anhê et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut (2014). PMID 25080446
- Gurley BJ et al. Decaffeinated Green Tea Extract Does Not Elicit Hepatotoxic Effects and Modulates the Gut Microbiome in Lean B6C3F₁ Mice. Nutrients (2019). PMID 30987244
- Derrien M et al. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Applied and environmental microbiology (2008). PMID 18083887
- Maria Carlota Dao et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut (2015). PMID 26100928
- Ching‐Tang Shih et al. Akkermansia muciniphila is Negatively Correlated with Hemoglobin A1c in Refractory Diabetes. Microorganisms (2020). PMID 32899513
- Elena Biagi et al. Through Ageing, and Beyond: Gut Microbiota and Inflammatory Status in Seniors and Centenarians. PLoS ONE (2010). PMID 20498852
- Wang Fang et al. Gut Microbiota Community and Its Assembly Associated with Age and Diet in Chinese Centenarians. Journal of Microbiology and Biotechnology (2015). PMID 25839332
- Ojetti V et al. Efficacy of inulin supplementation in metabolic control and Akkermansia muciniphila levels in subjects with type 1 diabetes: a pilot study. European review for medical and pharmacological sciences (2026). PMID 41636295
- Liang X et al. Dietary fat alters goblet cell function and microbial bile acid metabolism to promote intestinal lipid absorption in mice. Nature microbiology (2026). PMID 42271159
- Chen T et al. Akkermansia muciniphila Protects Against Psychological Disorder-Induced Gut Microbiota-Mediated Colonic Mucosal Barrier Damage and Aggravation of Colitis. Frontiers in cellular and infection microbiology (2021). PMID 34722332
- Vancheswaran Gopalakrishnan et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (2017). PMID 29097493
- Basolo A et al. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nature medicine (2020). PMID 32235930
- Naito Y et al. Low Prevalence and Abundance of Akkermansia in Older Japanese Adults: Inverse Association with a Noodle-Based Dietary Pattern but Not with Physical Function. Microorganisms (2026). PMID 42655074
- Li S et al. Akkermansia muciniphila in cardiovascular diseases: opportunities and challenges. Frontiers in microbiology (2026). PMID 42422741
- Gray SM et al. Dietary Protein Source Mediates Colitis Pathogenesis Through Bacterial Modulation of Bile Acids. Cellular and molecular gastroenterology and hepatology (2026). PMID 42342152
- Dulai AS et al. The Gut Microbiome's Influence on Incretins and Impact on Blood Glucose Control. Biomedicines (2024). PMID 39767626
- Wenxuan Di et al. Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells. World Journal of Microbiology and Biotechnology (2024). PMID 38727988
- Li Y et al. Peptide LKLKLL is a more effective component of Akkermansia muciniphila which regulate glucolipid metabolism through GLP-1/GIP dual modulation. Gut microbes (2026). PMID 42473065
- European Food Safety Authority (NDA Panel) Safety of pasteurised Akkermansia muciniphila as a novel food pursuant to Regulation (EU) 2015/2283. European Food Safety Authority (NDA Panel) (2021). source
- Zhuxian Zhu et al. Landscape of tumoral ecosystem for enhanced anti-PD-1 immunotherapy by gut Akkermansia muciniphila. Cell Reports (2024). PMID 38819989
- Sharon Y. Geerlings et al. Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How?. Microorganisms (2018). PMID 30041463
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
